0001104659-24-077836.txt : 20240703 0001104659-24-077836.hdr.sgml : 20240703 20240703171810 ACCESSION NUMBER: 0001104659-24-077836 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231117 FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: White Mark K. CENTRAL INDEX KEY: 0001786183 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39202 FILM NUMBER: 241100943 MAIL ADDRESS: STREET 1: 227 7TH AVENUE NE CITY: ST. PETERSBURG STATE: FL ZIP: 33701 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Annovis Bio, Inc. CENTRAL INDEX KEY: 0001477845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262540421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 LINDENWOOD DRIVE, SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-875-3192 MAIL ADDRESS: STREET 1: 101 LINDENWOOD DRIVE, SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: QR Pharma, Inc. DATE OF NAME CHANGE: 20091202 4 1 tm2417696-5_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-11-17 0 0001477845 Annovis Bio, Inc. ANVS 0001786183 White Mark K. C/O ANNOVIS BIO, INC. 101 LINDENWOOD DR, SUITE 225 MALVERN PA 19355 1 0 0 0 0 Stock Option (right to buy) 6.07 2023-11-17 4 A 0 26200 0 A 2033-11-17 Common Stock 26200 26200 D Stock Option (right to buy) 7.39 2023-11-27 4 A 0 2146 0 A 2033-11-27 Common Stock 2146 2146 D Stock Option (right to buy) 5.27 2024-07-01 4 A 0 20000 0 A 2034-07-01 Common Stock 20000 20000 D On June 12, 2024, stockholders of Annovis Bio, Inc. ("the Company") approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. The stock option shall vest immediately upon grant date. The stock option was granted in consideration for consulting services that reporting person will perform for the Company. The stock option shall vest in quarterly increments, based upon the services performed by the reporting person under the related Consulting Agreement. /s/ Maria Maccecchini Attorney-in-Fact 2024-07-03